Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model.
Front Immunol. 2023 Jun 19;14:1188605. doi: 10.3389/fimmu.2023.1188605. eCollection 2023.
Front Immunol. 2023.
PMID: 37409116
Free PMC article.
OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza.
Del Campo J, Bouley J, Chevandier M, Rousset C, Haller M, Indalecio A, Guyon-Gellin D, Le Vert A, Hill F, Djebali S, Leverrier Y, Marvel J, Combadière B, Nicolas F.
Del Campo J, et al. Among authors: chevandier m.
Front Immunol. 2021 Jun 10;12:678483. doi: 10.3389/fimmu.2021.678483. eCollection 2021.
Front Immunol. 2021.
PMID: 34177921
Free PMC article.
Item in Clipboard
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.
Withanage K, De Coster I, Cools N, Viviani S, Tourneur J, Chevandier M, Lambiel M, Willems P, Le Vert A, Nicolas F, Van Damme P.
Withanage K, et al. Among authors: chevandier m.
J Infect Dis. 2022 Aug 12;226(1):119-127. doi: 10.1093/infdis/jiab532.
J Infect Dis. 2022.
PMID: 34653245
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite